American Hospital Association December 4, 2024

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex Pharmaceuticals (manufacturer of Casgevy) will participate in its Cell and Gene Therapy Access Model. The voluntary model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Govt Agencies, Payment Models, Pharma / Biotech, Value Based
Related Articles:
Where US hospitals stand on value of heart attack care: 5 things to know
ACA enrollment breaks records again in 2025
Getting ready for the new Five-Star ratings
CMS issues flurry of Medicare fines to payers
ACP expresses support for proposed Medicare $2 Drug List Model

Share This Article